Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TOMVI - Health Canada Drug Approval Details

Approvals/Health Canada/TOMVI

Authorized

STANDARD

TOMVI

Sterimax Inc🇨🇦 Health Canada

Approval Date: Jul 4, 2025
Approval ID: e0416041817115b7
Company: Sterimax Inc
Type: Standard

Approval Details

Approval Id: e0416041817115b7
Drug Approval Canada Name: TOMVI
Product Name: TOMVI
Status: Marketed
Status Date: 2020-09-14
Original Market Date: 2020-09-14
Din: 02498650
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravenous
Schedule: Prescription
Ahfs: 28:04.08
Atc Original: N01AX07 ETOMIDATE
Atc Name: n 01 ax 07
Aig Number: 0162234001
Company Name: Sterimax Inc
Company Address: 2770 Portland Drive, Oakville, Ontario, Canada, L6H 6R4

Active Ingredients

ETOMIDATE

2 MG / ML

Authorized

Quick Info

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

e0416041817115b7

Type

Standard

Back to Health Canada Approvals